MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PBYI had -$1,137K decrease in cash & cash equivalents over the period. $9,663K in free cash flow.

Cash Flow Overview

Change in Cash
-$1,137K
Free Cash flow
$9,663K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income
17,673 -
Depreciation and amortization
8,281 -
Stock-based compensation
5,327 -
Provision for credit loss recovery
-362 -
Disposal of property and equipment
-4 -
Accounts receivable, net
1,192 -
Inventory, net
752 -
Prepaid expenses and other
-393 -
Other current assets
139 -
Accounts payable
877 -
Operating lease assets and liabilities, net
1,266 -
Accrued expenses and other
279 -
Post-marketing commitment liability
-1,740 -
Net cash provided by operating activities
9,689 17,694
Purchase of property and equipment
26 81
Purchase of available-for-sale securities
26,784 34,420
Maturity of available-for-sale securities
27,316 24,784
Net cash used in investing activities
506 -9,717
Net proceeds from shares issued under employee stock plans
0 130
Payment of debt
11,110 22,220
Payment of exit costs
222 444
Net cash used in financing activities
-11,332 -22,534
Net decrease in cash, cash equivalents and restricted cash
-1,137 -14,557
Cash and cash equivalents at beginning of period
71,310 -
Cash and cash equivalents at end of period
55,616 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

PUMA BIOTECHNOLOGY, INC. (PBYI)

PUMA BIOTECHNOLOGY, INC. (PBYI)